Board of Directors

We are supported by a highly experienced board of directors with broad industry knowledge. 

 

David Meek

Non-Executive Member

(Chairman) David Meek has served as a member of our board since June 2018. Mr. Meek has 30 years of experience in the pharmaceutical industry, where he has held various global executive positions in major pharmaceutical and biotechnology companies. Mr. Meek was appointed President & CEO of FerGene, a gene therapy biotech company focused on cancer, in January 2020. Prior to this, Mr. Meek served as CEO of Ipsen from July 2016 to December 2019, and as Executive Vice President and President of the oncology division of Baxalta. Mr. Meek also served as Chief Commercial Officer for Endocyte, a biotech focused on oncology, and spent eight years at Novartis as a global franchise head, CEO of Novartis Canada, and region head of oncology for northern, central and Eastern Europe. Earlier in his career, Mr. Meek spent 14 years at Johnson & Johnson and Janssen Pharmaceutica, where he held a variety of senior U.S. sales and marketing positions. Mr. Meek serves as chairman of the board for Entasis Therapeutics.  He holds a B.A. in Management from the University of Cincinnati.

 

Madhavan Balachandran

Non-Executive Member

Madhavan Balachandran has served as a member of our board since September 2017. Mr. Balachandran is a pharmaceutical industry executive and has more than 40 years of experience in manufacturing and operations. He was previously with Amgen Inc., where he served as Executive Vice President of Operations, overseeing global operations and reporting directly to the CEO. Mr. Balachandran held similar positions at Copley Pharmaceuticals Inc. and Burroughs Wellcome Co. Mr. Balachandran holds a Master's degree in Business Administration from East Carolina University, a Master's degree in Chemical Engineering from State University of New York and a Bachelor's degree in Technology from Indian Institute of Technology.

 

Robert Gut

Non-Executive Member

Robert Gut first became a member of our board in June 2018, and served as our Chief Medical Officer from August 2018 until August 2020. Dr. Gut has 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc., where he headed the company's U.S. Biopharm Medical organization with leading products in hemophilia, including NovoSeven® (Factor VIIa), NovoEight® (Factor VIII), Tretten® (Factor XIII) and Factor IX. Dr. Gut's contributions helped achieve nine different FDA approvals and the successful launches of those products. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research. Dr. Gut received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.

 

Matt Kapusta

Executive Member

Matt Kapusta joined uniQure as our chief financial officer in January 2015 and was elected to our Management Board at the 2015 annual general meeting. In December 2016 he was appointed our chief executive officer.  Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics from 2011 to 2014, responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance for Smith & Nephew Orthopaedics. Mr. Kapusta's career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. Mr. Kapusta holds a Master of Business Administration from New York University's Stern School of Business, a Bachelor of Business Administration from University of Michigan's Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.
 

Jack Kaye

Non-Executive Member

Jack Kaye is currently chairman of our Audit Committee and a member of the Compensation Committee of Dyadic International, Inc.  Mr. Kaye began his career at Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006. At Deloitte, he was responsible for servicing a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley matters. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than 20 years. Mr. Kaye has a Bachelor of Business Administration from Baruch College and is a Certified Public Accountant.

 

Leonard Post

Non-Executive Member

Leonard Post has served as a member of our supervisory board since 2020.  Dr. Post has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals. Since 2016, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics and its sister company, Virtuoso Therapeutics, both of which are developing oncology therapeutics. From 2010 until 2016, Dr. Post served in various positions at BioMarin, including Chief Scientific Officer, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A.  Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow.  He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin. 

 

Paula Soteropoulos

Non-Executive Member

Paula Soteropoulos has served as a member of our supervisory board since July 2013. She also serves as Executive Chairman of Ensoma and as a member of the board of Rallybio. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building.  Most recently, she served as the chief executive officer of Akcea Therapeutics.  Ms. Soteropoulos was the founding President and CEO in 2015 and led the company through its IPO on NASDAQ in 2017, as well as significant growth: employing over 270 staff in thirteen countries, six drugs in its portfolio with 2 rare disease drug approvals. From July 2013 to December 2014, she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a bachelor of science degree in chemical engineering and a master of science degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. 

 

 

Jeremy Springhorn

Non-Executive Member

Jeremy Springhorn has served as a member of our Board since September 2017. Since April 2021, Dr. Springhorn has been Chief Executive Officer at Newco, a 5AM Ventures Company. Prior to taking his position at Newco, Dr. Springhorn served as Chief Business Officer of Syros Pharmaceuticals from June 2017 until April 2021.  He previously served as Partner, Corporate Development at Flagship Pioneering from March 2015 until June 2017, where he worked with VentureLabs (in helping companies in various strategic and corporate development capacities and in creating next generation startups) and Flagship’s Corporate Limited Partners. Prior to joining Flagship, Dr. Springhorn was one of the original scientists at Alexion Pharmaceuticals, where he played an integral role in its antibody engineering capabilities and was one of the original inventors of the drug Soliris®.  Dr. Springhorn started at Alexion in 1992 where he served in various leadership roles in R&D before switching to Business Development in 2006. Dr. Springhorn was Vice President of Corporate Strategy and Business Development at Alexion from 2006 until March 2015.  Prior to 1992, Dr. Springhorn received his Ph.D. from Louisiana State University Medical Center in New Orleans and his BA from Colby College . Dr. Springhorn currently serves on the Board of Directors for NMD Pharma, Board of Advisors for Mythic Therapeutics and the Board of Visitors for Colby College.

 

 

 

The following table sets out the year in which the current term of office of each member of our Board of Directors is set to expire. 

Name

    

 

Position

    

Member Since

    

Term Expires

Mr. Matthew Kapusta

 

  

Executive Director

 

2016

 

2022

               

Mr. Madhavan Balachandran

 

 

Non-Executive Director

 

2017

 

2023

Mr. Robert Gut

 

 

Non-Executive Director

 

2018

 

2022

Mr. Jack Kaye

 

 

Non-Executive Director

 

2016

 

2023

Mr. David Meek

 

 

Non-Executive Director

 

2018

 

2024

Mr. Leonard Post

 

 

Non-Executive Director

 

2020

 

2023

Ms. Paula Soteropoulos

 

 

Non-Executive Director

 

2013

 

2024

Mr. Jeremy P. Springhorn

 

 

Non-Executive Director

 

2017

 

2023